Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RESMED INC Director's Dealing 2024

May 9, 2024

30071_dirs_2024-05-09_f9b0d56c-3bfc-4ebd-9995-b339ef2601d2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2024-05-07

Reporting Person: Farrell Michael J. (Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-05-07 ResMed Common Stock M 1176 $84.98 Acquired 441928 Direct
2024-05-07 ResMed Common Stock M 13507 $84.98 Acquired 455435 Direct
2024-05-07 ResMed Common Stock S 14683 $216.4963 Disposed 440752 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-05-07 ResMed Common Stock Options $84.98 M 1176 Disposed 2024-11-16 ResMed Common Stock (1176) Direct
2024-05-07 ResMed Common Stock Options $84.98 M 13507 Disposed 2024-11-16 ResMed Common Stock (13507) Direct

Holdings (Non-Derivative)

Security Shares Ownership
ResMed Common Stock 0 Indirect
ResMed Common Stock 4090 Indirect
ResMed Common Stock 0 Indirect

Footnotes

F1: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2: This transaction was executed in multiple trades at prices ranging from $215.71 - $217.08. The price reported above reflects the weighted average sale price.

F3: Represents date options first became exercisable. Options vest 1/3 per year.